Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-CURE-1: Pembrolizumab and Carboplatin in CTC+ HER2- Metastatic Breast Cancer
NCT03213041Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Sep 2017
- Primary completion
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in breast cancer, sponsored by Northwestern University. Primary endpoint: Progression-Free Survival at 3 years. Started Sep 2017; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03213041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213041.